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Abstract
Background and objective Some subjects with untreated peri-
odontitis exhibit elevated levels of distinct inflammatory
markers in serum. The aim of the study was to assess whether
nonsurgical periodontal therapy changes the levels of these
markers and lowers these peaks.
Methods Forty periodontally diseased subjects received non-
surgical periodontal therapy (full-mouth scaling and root
planing within 48 h) with either adjunctive systemic amoxi-
cillin and metronidazole (n=19) or placebo (n=21). Serum
samples, obtained at baseline (BL) and 3 months after treat-
ment (M3), were evaluated for 15 cytokines and 9 acute-phase
proteins using the Bio-Plex bead array multianalyte detection
system. For each analyte, peak values were defined as greater
than the mean+2 standard deviations (SD) of measurements
found in 40 periodontally healthy persons. Proportions were
compared using Fisher’s exact test.
Results AtM3, a significantly better primary clinical outcome
(persisting pockets of >4 mm with bleeding on probing) was
obtained in patients treated with scaling and root planing plus
antibiotics compared to those receiving placebo (3.3±5.1 vs.
6.8±7.8 pockets per patient, p<0.05). The levels of cytokines
and acute-phase proteins of periodontitis patients were usually
below the mean+2 SD threshold of healthy persons.
However, values above threshold were found in some indi-
viduals. Eleven patients showed a peak value of one analyte,
and seven patients showed two peaks. In the remaining 12
patients, between three and ten analytes showed peak values.
Therapy greatly reduced the number of subjects with four or
more peaks (BL, 11 subjects; M3, 1 subject, p=0.003). With
regards to the reduction of peaks, no specific benefit of ad-
junctive antibiotics could be seen.
Conclusion Subjects with untreated periodontitis may show
high peaks for several inflammatory markers in serum simul-
taneously. Nonsurgical periodontal treatment with or without
antibiotics reduced most of these peak levels.
Keywords Nonsurgical periodontal therapy . Antibiotics .
Serum . Inflammatorymediators
Introduction
Periodontitis is associated with elevated serum inflammatory
markers (for review, see [1]). This suggests that periodontitis
may have an impact on systemic health and insinuates that
efforts to maintain or restitute periodontal health may contrib-
ute to systemic health. Studies have indicated that biological
markers of systemic conditions like atherosclerosis are more
prevalent in periodontitis patients than in age- and gender-
matched controls [2]. However, the currently available data on
periodontal systemic associations are rather heterogeneous
[3], and the evidence that periodontal therapy has an impact
on systemic health is limited [4]. A few studies have tried to
elucidate whether clinically successful periodontal treatment
can reduce the levels of serological markers and have yielded
inhomogeneous results. A preliminary intervention study in-
dicated that standard nonsurgical therapy (scaling and root
planing (SRP)) might be able to change levels of IL-6 and
C-reactive protein [5]. In a comparative study, SRP reduced
One-sentence summary Nonsurgical periodontal treatment with or
without antibiotics reduced peak levels of several inflammatory markers
in serum of subjects with periodontitis.
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levels of IL-6 and C-reactive protein and, if local antibiotics
were added, also total and LDL cholesterol in serum [6]. In
another study, however, periodontal therapy improved clinical
and microbiological parameters but did not influence the levels
of serum analytes [7]. In patients with chronic periodontitis and
known coronary artery disease, SRP reduced high-sensitivity
C-reactive proteins (hsCRPs) and white blood cell counts;
however, tumor necrosis factor alpha (TNF-α) levels showed
no statistically significant reduction [8]. In patients with meta-
bolic syndrome, CRP levels decreased after nonsurgical peri-
odontal therapy, with or without adjunctive antibiotics [9]. A
systematic review has concluded that plasma CRP in periodon-
titis is elevated, and modest evidence indicates an effect of
periodontal therapy in lowering these levels [10].
Technological developments have made it possible to detect
and quantify a range of various biological markers in relatively
small fluid specimens simultaneously. A high-throughput bead-
based suspension array immunoassay system can assess up to
100 analytes in a sample volume of 25 to 50 μL [11]. The
quantification of multiple markers in one single sample can
provide information on interactions that are inaccessible by
studying single markers individually. The potential presence
of very high values of several analytes at the same time was our
particular focus, because such values tend to be disregarded as
outliers in traditional single-marker analyses. A preliminary
examination indeed suggested that among patients with untreat-
ed periodontitis, a few might exhibit high levels of several
distinct inflammatory markers at the same time [12]. The
presence and the disappearance of multiple extreme values
may be biologically important in affected individuals, even if
this does not concern all participants of a trial. The clustering of
peaks has not been studied in periodontitis patients so far, and
its clinical relevance is unknown. Studies on changes of sero-
logical inflammatory markers after periodontal therapy con-
ducted so far rather looked at mean or median changes of single
serological markers. The purpose of the present investigation
was to further investigate this phenomenon by measuring a
range of 24 analytes in the serum of periodontally diseased
patients before and after nonsurgical periodontal therapy. This
analysis is part of a large randomized clinical trial on the
adjunctive effects of antibiotics given at different time points
during periodontal therapy. For the present analysis, we focus
on the outcomes at the 3-month reevaluation after initial ther-
apy, and the differential effect of the antibiotics is not the
primary subject here.
Material and methods
Participants and study design
Participants were recruited among patients seeking periodon-
tal treatment or consulting for a routine dental checkup at the
School of Dental Medicine of the University of Geneva be-
tween April 2009 and August 2011. Forty patients with un-
treated moderate-to-advanced periodontitis [presence of at
least four teeth with a probing pocket depth (PD) of >4 mm,
clinical attachment loss of at least 2 mm, and radiographic
evidence of bone loss] participated in a single-center, random-
ized, placebo-controlled, parallel-group, and double-masked
trial. In addition, 40 persons without evidence for past or
present periodontal disease (absence of periodontal pockets
with PD of >3 mm, absence of clinical attachment loss of
>1 mm, and no radiographic evidence of bone loss) were
included to provide a single venous blood sample. All partic-
ipants were systemically healthy, within an age range of 25–
70 years, and had at least 12 scorable teeth (not including third
molars, teeth with orthodontic appliances, bridges, crowns, or
implants). Exclusion criteria were systemic illnesses (i.e., dia-
betes mellitus, cancer, HIV, bone metabolic diseases, or disor-
ders that compromise wound healing, radiation, or immuno-
suppressive therapy), pregnancy or lactation, systemic antibi-
otics taken within the previous 2 months, use of nonsteroid
anti-inflammatory drugs, confirmed or suspected intolerance to
5-nitroimidazole derivatives or amoxicillin, and subgingival
SRP or surgical periodontal therapy in the last year.
The Ethical Committee of the University Hospitals of Ge-
neva, Geneva, Switzerland, approved the protocol. Research
was conducted according to the principles outlined in the
Declaration of Helsinki on human medical experimentation.
Written informed consent was obtained from all participants.
Clinical protocol
Venous blood samples were drawn from all 80 participants.
The 40 individuals with periodontitis were further examined
and treated according to the clinical protocol outlined below.
Blood samples were again obtained from the latter 12 weeks
after therapy.
The clinical part of the study involved the examiner (AA),
who obtained informed consent, organized the treatment ses-
sions, and recorded all data, and the operator (NC), who
provided the therapy. The therapist was unaware of the re-
corded data, except for the periodontal pocket chart that he
needed to deliver the treatment.
The operator removed supragingival deposits and gave oral
hygiene instructions and if necessary gave reinforcement of
oral hygiene during recall visits. Once the subjects had
reached an appropriate level of plaque control, they were
scheduled to receive subgingival treatment within 1 month
by the operator. Immediately before treatment, the examiner
recorded the periodontal parameters. The operator treated the
periodontally diseased teeth with thorough SRP to the depth
of the pocket under local anesthesia. He first used ultrasonic
instruments, then Gracey curettes, and finally irrigated the
pockets with a 0.1 % aqueous solution of chlorhexidine.
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Subjects were instructed to rinse the mouth twice daily during
the next 10 days with 0.2 % chlorhexidine. SRP was complet-
ed within 48 h and usually required two sessions.
At the end of the last session, each subject received a
neutral package, prepared by the pharmacy of the Geneva
University Hospital, containing either a test or placebo med-
ication, and was advised to start with the drug regimen in the
evening of the same day. Patients in the test group received
500 mg metronidazole and 375 mg amoxicillin, to be taken
three times per day during 7 days, and patients in the control
group received similar-looking placebos. The treatment was
allocated using a computer-generated randomization list
concealed to the patient, the clinical examiner, and the therapist.
The examiner called the subjects after 1 week, and after
1 month. Medical history, any concomitant medication, and
any adverse events or serious adverse events were recorded.
The first posttreatment visit also served as a compliance control,
as subjects were asked to return any medication that remained.
Immediately before (baseline (BL)) and 3 months after
therapy (M3), the following clinical parameters were recorded
on six sites of each tooth with a pocket of >4 mm at baseline:
Gingival Index (GI) [13], PD and recession (REC; positive if
gingival margin located apical, negative if located coronal to
the cementoenamel junction), bleeding upon probing (BOP),
or suppuration.
Blood sampling and processing
Five milliliters of blood was obtained by venipuncture using
tubes without anticoagulant. The specimens were immediately
centrifuged at 1,300g for 10 min. Twomilliliters of serum was
stored at −70 °C until the day of analysis.
We used a multiplex fluorescent bead-based immunoassay
and the Bio-Plex 200 Suspension Array System (Bio-Rad
Laboratories, Hercules, CA, USA) to assess two panels of
serum markers. The first panel included the following 15
cytokines: IL-1β, IL-1ra, IL-4, IL-6, IL-8, IL-10, IL-12, IL-
17, basic FGF, G-CSF, GM-CSF, IFN-γ, MIP-1β VEGF, and
TNF-α (kit M5000HIXIL, Bio-Rad Laboratories, Hercules,
CA, USA). The second panel included the following nine
acute-phase proteins: α2M, haptoglobin, CRP, serum amyloid
P and A, ferritin, fibrinogen, tissue plasminogen activator, and
procalcitonin (kits 171A4009M and 171A4007M, Bio-Rad
Laboratories, Hercules, CA, USA). The assays were per-
formed following the manufacturer’s instructions. Briefly,
96-well filter plates were pre-wetted with assay buffer, and
the solution was aspirated from the wells using a vacuum
filter. Microsphere beads coated with monoclonal antibodies
against the 24 target analytes were added to the wells. Serum
samples, controls, and standards were added in separate wells
and incubated 30 min for the 15-plex panel and 1 h for the
acute-phase protein panel. The wells were washed using the
vacuum filter, and a mixture of biotinylated secondary
antibodies was added. After incubation for 30 min and wash-
ing of the plates, streptavidin conjugated to the fluorescent
protein phycoerythrin (streptavidin-PE) was added to the
wells and incubated for 10 min. After washing to remove
the unbound reagents, the assay buffer was added to the wells,
and the beads (minimum of 100 per analyte) were analyzed in
the Bio-Plex 200 Suspension Array System. For the 15-plex
panel, the detection limit of the assay was 1 pg/ml. For the
acute-phase protein panel, the limit of detection was 1 ng/ml,
with the exception of ferritin, procalcitonin, and tissue plas-
minogen activator, where the detection limit was 1 pg/ml.
Statistical analysis
Because not all data were normally distributed, differences
between placebo and test groups were analyzed using
Wilcoxon matched-pair signed-rank test, a nonparametric test.
Bio-Plex Manager 3.0 (Bio-Rad, Hercules, CA, USA) was
used to analyze the readout. All analytes had a very skewed
distribution, with most patients having normal values and a
few patients having extreme values. Thus, we dichotomized
each analyte into a normal versus extreme value. The cutoffs
used to determine these peak values were defined as greater
than the mean+2 standard deviations (SD) found in 40 unre-
lated periodontally healthy persons. If an analyte had a detec-
tion frequency below 25 % in the healthy subjects, the cutoff
was set at the respective detection level. To calculate mean
values, a constant (0.1) was added to remove zero values.
Proportions of peaks between treatment groups were com-
pared using Fisher’s exact tests. p values of <0.05 were
accepted for statistical significance. The statistical software
R (version 2.15.1, The R Foundation for Statistical Comput-
ing, Vienna, Austria) was used for all analyses.
Results
The mean age of the healthy subjects was 37.2±11.0, and of 26
females and 14males, 10%were smokers. Themean age of the
patients was 46.8±8.5, and of 20 females and 20 males, 35 %
were smokers. In these patients, no significant differences were
found between groups for the demographic variables.
The clinical results of the study before and 3 months after
treatment are summarized in Table 1. All 40 enrolled patients
with periodontitis could be followed up to M3. A total of
3,612 sites (6 on a total of 602 periodontally diseased teeth
with a pocket of >4 mm at BL; pockets of >4 mm had a mean
PD of 6.5 mm) were clinically monitored at BL and M3. At
BL, differences between groups were not significant. In con-
trast, at M3, a significantly better primary clinical outcome
was obtained in patients treated with full-mouth SRP plus
amoxicillin and metronidazole compared to those receiving
placebo. Those treated with antibiotics had fewer persisting
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pockets of >4 mm with BOP than those treated with placebo.
In the patients of the placebo group, on average 6.8±7.8
pockets of >4 mm with BOP could still be found, whereas
mere 3.3±5.1 sites in this category were still detected in the
test group.
A total of 120 serum samples were collected and analyzed
for the presence of 15 cytokines and 9 acute-phase proteins.
Table 2 shows the number of positive samples of all analytes
in the 40 periodontally healthy subjects and, if detected in at
least 25 % of the specimens, the mean values, standard devi-
ations, and mean+2 SD. For the analytes detected in at least
25 %, the mean+2 SD served as a threshold to define peak
values in periodontitis patients. Six cytokines could not be
detected in any serum sample (IL-4, IL-17, b-FGF, G-CSF,
GM-CSF, and IFN-γ), and three (IL-1 β, IL-6, and IL-10)
were detected with a frequency below 25 %. For those nine
cytokines, each positive reading in a patient was considered as
a peak (i.e., the cutoff for inclusion was set at the respective
level of detection).
Table 3 shows the incidence and range of peak values of 15
cytokines and 9 acute-phase proteins in 40 periodontitis pa-
tients before and after therapy. For example, four patients
presented peak values for IL-1β at baseline and eight for IL-
1ra. These peak values ranged between 4.8 and 226.5 and
between 21.7 and 127.3, respectively. At M3, none of the
patients still presented a peak for IL-1β, and only a single case
still demonstrated a peak for IL-1ra.
For five biomarkers with high incidence of peaks of base-
line, i.e., serum amyloid A, IL-1ra, IL-12, MIP-1β, and
procalcitonin, treatment significantly reduced the number of
subjects with peaks (p<0.05). Figure 1 shows a scatter plot for
serum amyloid A, comparing the values before and after
therapy for each subject. For one analyte, the number of
subjects with peaks increased significantly after treatment
(haptoglobin, p=0.01).
We then calculated for each individual how many of the 24
analytes showed a peak value at baseline and howmany peaks
persisted after therapy, with or without antibiotics. As Fig. 2a
shows, none of the 24 analytes were above threshold before
treatment in ten participants. A single analyte showed a
peak value in 11 patients, and two peaks were found in
seven patients. In the remaining 12 patients, between
three and ten analytes showed peak values. For individ-
uals with two or more peaks, the mean values of PD
and BOP were within the range of the other patients
(PD, 4.41; BOP, 86.6).
Table 1 Clinical findings at baseline and after 3 months by treatment
group. Data are means (standard deviation), n=40 participants
Parameters Baseline Month 3
Placebo Test Placebo Test
Participants, n 21 19 21 19
PD, mm 4.4 (2.0) 4.7 (2.3) 2.9 (1.3) 2.6 (1.0)
REC, mm 0.9 (1.0) 0.6 (0.8) 1.2 (1.3) 1.0 (1.0)
BOP, +% 90.7 (29.0) 89.9 (30.1) 37.8 (49.5)* 27.5 (44.7)*
GI, score 0.9 (0.6) 1.0 (0.6) 0.2 (0.4) 0.2 (0.4)
PD>4 and BOP+,
n sites/person
32.2 (19.8) 37.2 (34.8) 6.8 (7.8)* 3.3 (5.1)*
PDprobing pocket depth, REC recession,BOPbleeding upon probing,GI
Gingival Index
*p<0.05, difference between placebo and test
Table 2 Detection frequency of 15 cytokines and 9 acute-phase proteins
in 40 periodontally healthy persons and, if detected in more than ten
(25 %) cases, standard deviation (SD) and mean+2 SD. Mean+2 SD
values served as a threshold to define peak values in periodontitis patients
Analyte N (%) Mean (SD) Mean+2 SD (cutoff)a
IL-1β, pg/ml 1 (2.5) – 1a
IL-1ra, pg/ml 35 (87.5) 4.3 (6.9) 18.1
IL-4, pg/ml 0 (0.0) – 1a
IL-6, pg/ml 2 (5.0) – 1a
IL-8, pg/ml 29 8.0 (9.7) 27.3
IL-10, pg/ml 9 (22.5) – 1a
IL-12-p70, pg/ml 40 (100.0) 29.5 (16.9) 63.3
IL-17, pg/ml 0 (0.0) – 1a
basic-FGF, pg/ml 0 (0.0) – 1a
G-CSF, pg/ml 0 (0.0) – 1a
GM-CSF, pg/ml 0 (0.0) – 1a
IFN-γ, pg/ml 0 (0.0) – 1a
MIP-1β, pg/ml 40 (100.0) 143.0 (58.0) 259.1
TNF-α, pg/ml 18 (45.0) 14.0 (30.2) 74.3
VEGF, pg/ml 40 (100.0) 193.4 (137.6) 468.7
α2M, mg/ml 40 (100.0) 1.9 (0.7) 3.3
CRP, μg/ml 40 (100.0) 1.9 (3.9) 9.8
Haptoglobin, mg/ml 40 (100.0) 1.4 (1.5) 4.5
Serum amyloid P,
μg/ml
40 (100.0) 44.7 (13.9) 72.6
Ferritin, ng/ml 40 (100.0) 58.8 (47.6) 154.1
Fibrinogen, μg/ml 40 (100.0) 2.5 (0.6) 3.8
Procalcitonin, ng/ml 36 (90.0) 2.2 (1.4) 5.0
Serum amyloid A,
μg/ml
40 (100.0) 3.4 (2.8) 8.9
TP activator, ng/ml 17 (42.5) 6.3 (8.6) 23.5
IL-1β interleukin-1 beta, IL-1ra interleukin-1 receptor antagonist, IL-4
interleukin-4, IL-6 interleukin-6, IL-8 interleukin-8, IL-10 interleukin-10,
IL-12 interleukin-12, IL-17 interleukin-17, b-FGFbasic fibroblast growth
factor, G-CSF granulocyte colony-stimulating factor, GM-CSF granulo-
cyte macrophage colony-stimulating factor, IFN-γ interferon gamma,
MIP-1β macrophage inflammatory protein beta, TNF-α tumor necrosis
factor alpha, VEGF vascular endothelial growth factor, α2M alpha-2
macroglobulin, CRPC-reactive protein, TP tissue plasminogen
a If an analyte was detected in less than 25%, the detection level was used
as a cutoff
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Figure 2b shows the number of analytes with peak values
per subject after therapy. Therapy did not significantly reduce
the number of subjects having at least one peak (BL, 30
subjects; M3, 27 subjects; p=0.62). The number of subjects
with four or more peaks, however, was greatly reduced (BL,
11 subjects; M3, 1 subject; p=0.003). With regards to the
reduction of peaks, no specific benefit of adjunctive antibi-
otics could be seen. A single patient still showed eight peaks
after treatment. This particular subject had eight peaks at BL
also, was treated with antibiotics, and responded well to
therapy as far as clinical parameters are concerned (mean PD
at BL, 6.26 mm; BOP at BL, 100 %; PD after therapy,
3.07 mm; BOP after therapy, 39.9 %).
Table 4 shows the mean serum biomarker levels in
periodontitis patients per treatment group at baseline and
M3 of those 13 analytes with a detection frequency of
>75 %. The levels were significantly lower at M3 than
those at baseline for most of these markers. Differences
between groups were not significant.
There were no serious adverse events. The number of
patients reporting a stomach upset was similar in both groups
(three in the placebo group and three in the test group). One
patient treated with antibiotics and three in the placebo group
reported gastrointestinal problems, notably diarrhea. All other
events were sporadic.
Discussion
Wemeasured a range of 24 analytes in the serum of periodon-
tally diseased patients before and 3 months after nonsurgical
periodontal therapy and assessed to what extent levels of these
analytes can be modified by treatment. A high-throughput
technique was used to assess the expression profile of 15
cytokines and 9 acute-phase proteins in serum. The Bio-Plex
200 Suspension Array System is a flow-based dual-laser
system that detects and measures molecules bound to the
surfaces of fluorescent microspheres, thus providing a highly
accurate analysis of serum, culture media, and other biological
samples. Although the ELISA technique remains the gold
standard for measuring inflammatory mediators, this new
technology offers a number of advantages, such as the
Table 3 Incidence (number and
frequency) and range of peak
values (readings above mean+2
SD of healthy persons) of 15 cy-
tokines and 9 acute-phase pro-
teins in 40 periodontitis patients
before and after therapy
IL-1β interleukin-1 beta, IL-1ra
interleukin-1 receptor antagonist,
IL-4 interleukin-4, IL-6 interleu-
kin-6, IL-8 interleukin-8, IL-10
interleukin-10, IL-12 interleukin-
12, IL-17 interleukin-17, b-FGF
basic fibroblast growth factor,
G-CSF granulocyte colony-stim-
ulating factor, GM-CSF granulo-
cyte macrophage colony-stimu-
lating factor, IFN-γ interferon
gamma, MIP-1βmacrophage in-
flammatory protein beta, TNF-α
tumor necrosis factor alpha,
VEGF vascular endothelial
growth factor, α2M alpha-2 mac-
roglobulin, CRPC-reactive pro-
tein, TP tissue plasminogen
Analyte Baseline Month 3
N (%) Range N (%) Range
IL-1β, pg/ml 4 (10.0) 4.8–226.5 0 (0.0) –
IL-1ra, pg/ml 8 (20.0) 21.7–127.3 1 (2.5) 32.0
IL-4, pg/ml 1 (2.5) 2.0 0 (0.0) –
IL-6, pg/ml 1 (2.5) 216.3 0 (0.0) –
IL-8, pg/ml 1 (2.5) 38.3 1 (2.5) 39.6
IL-10, pg/ml 4 (10.0) 1.4–61.6 5 (12.5) 1.4–4.9
IL-12-p70, pg/ml 5 (12.5) 66.7–125.8 0 (0.0) –
IL-17, pg/ml 1 (2.5) 2.3 0 (0.0) –
basic-FGF, pg/ml 2 (5.0) 18.7–36.3 1 (2.5) 11.9
G-CSF, pg/ml 1 (2.5) 29.8 0 (0.0) –
GM-CSF, pg/ml 2 (5.0) 17.2–162.6 0 (0.0) –
IFN-γ, pg/ml 3 (7.5) 13.2–5,087.0 4 (10.0) 4.2–49.3
MIP-1β, pg/ml 6 (15.0) 260.5–791.2 0 (0.0) –
TNF-α, pg/ml 1 (2.5) 140.4 0 (0.0) –
VEGF, pg/ml 5 (12.5) 538.6–2,456.2 3 (7.5) 525.7–5,518.7
α2M, mg/ml 0 (0.0) – 0 (0.0) –
CRP, μg/ml 4 (10.0) 13.4–52.6 3 (7.5) 14.1–33.4
Haptoglobin, mg/ml 5 (12.5) 5.1–7.9 16 (40.0) 5.8–9.4
Serum amyloid P, μg/ml 6 (15.0) 73.3–91.7 10 (25.0) 74.6–138.1
Ferritin, ng/ml 8 (20.0) 212.2–505.8 9 (22.5) 187.6–418.5
Fibrinogen, μg/ml 1 (2.5) 3.9 0 (0.0) –
Procalcitonin, ng/ml 6 (15.0) 5.4–6.3 0 (0.0) –
Serum amyloid A, μg/ml 14 (35.0) 9.7–20.0 2 (5.0) 13.1–30.8
TP activator, ng/ml 4 (10.0) 23.9–28.0 0 (0.0) –
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simultaneous determination of up to 100 different analytes in a
single sample, less sample volume, ability to detect different
proteins across a broad range of concentrations, and efficiency
in terms of time and cost [14, 15]. The cytokine multiplex
assays were found to be comparable in sensitivity, accuracy,
and reproducibility to ELISAs for the same analytes [16].
So far, most of the studies comparing levels of bio-
chemical parameters between healthy subjects and peri-
odontitis patients, or before and after therapy in dis-
eased subjects, mean or median levels were presented,
and comparisons were made using Mann-Whitney U
tests. Another way to analyze the overall systemic re-
sponse to treatment is by calculating the summary in-
flammatory score (SIS); for each time point, a standard-
ized within-person z score is created for each analyte,
and then by averaging the different analyte scores, the
SIS is obtained for each patient at each time point.
Using this approach, heterogeneous responses to peri-
odontal therapy were found that correlated poorly with
clinical and infectious markers of periodontitis [17].
Due to the distribution patterns of these markers
found in preliminary analyses [7, 12], the present anal-
ysis focused on the incidence of high values of multi-
ple analytes, rather than on mean or median changes or
a summary score, assuming that multiple high values
of several markers may be more consequential for
systemic health than elevated mean levels of single
markers. We show for the first time that some patients
with untreated periodontitis indeed present high peaks
for several inflammatory markers simultaneously and,
furthermore, that simple, nonsurgical periodontal treat-
ment with or without antibiotics has the potential to
eliminate multiple peaks.
The mean+2 SD of each analyte, determined in 40
periodontally healthy persons unrelated to the trial co-
hort, served as a threshold to define peak values for the
40 periodontitis patients participating in the trial. Before
therapy, 11 of the 40 patients enrolled in the trial
exhibited levels above a threshold of four and up to
ten inflammatory markers at the same time. After treat-
ment, the number of subjects with four or more peaks
was significantly reduced. Only a single patient
remained with multiple peaks (eight analytes above the
threshold). The fact that this person was the only one
having also eight peaks at BL and responding well to
therapy suggests that the reason for this unusual pattern
was not periodontal disease. The number of subjects with
peaks increased significantly after treatment for only one
analyte (haptoglobin, p=0.01). This was probably due to
random variability. We are aware of the limitations inferring
a casual relationship between peak values of multiple inflam-
matory mediators in serum and the pathogenesis of periodon-
tal disease, since this pattern was not recognized in every
patient and we cannot determine its origin. However, several
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Fig. 1 Scatter plot for serum
amyloid A. Each dot represents
one case of 40 periodontally
diseased subjects before and after
therapy (μg/ml)
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subjects belonging exclusively to the periodontitis group pre-
sented extreme values for an important number of analytes.
Conflicting results on the mean or median effects of peri-
odontal therapy on systemic inflammation have been reported
previously. Whereas a significant increase in plasma TNF-α,
CRP and IL-6 levels has been found immediately after non-
surgical periodontal therapy in some trials [6, 18, 19], other
studies found no changes in the serum levels of these media-
tors 3 months after therapy [20]. Six months after treatment,
significant reductions in serum IL-6 and CRP were found
especially in subjects who responded better than average to
the delivered periodontal therapy [5]. However, in another
study, the same group reported marked increases in the serum
levels of CRP and serum amyloid A only 24 h after treatment
[21]. Responses of systemic inflammatory biomarkers were
highly heterogeneous following periodontal therapy in a trial
of another group where a large number of analytes was
assessed simultaneously [17]. One third of the patients
showed a marked reduction and one fourth a pronounced
increase, and the remainder of the patients showed no change
in systemic inflammation.
In the medical literature, IL-6 has been described as
a reliable marker for systemic inflammation. Peak
values of plasma IL-6 and other peripheral markers of
inflammation were assessed in the first week of ische-
mic stroke in one study. Significant correlations between
peak plasma IL-6 in the first week of ischemic stroke
with both brain infarct volume and outcome at 3 months
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Fig. 2 Number of biomarker
peaks per subject before (a) and
after (b) therapy. Total number of
biomarkers is 24, and the number
of cases is 40
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were demonstrated [22]. In a study including patients
with or without periprosthetic infection following total
hip and knee arthroplasty, normal values of IL-6 were
defined as those below a cutoff of 10 pg/ml [23]. In our
study, the threshold for IL-6 was similar (14.3 pg/ml).
Only one patient had a value above this threshold
before and none after therapy. However, in a large
population of African children without or with malaria
[24], the mean values were 54 pg/ml in healthy and
485 pg/ml in severely diseased subjects. Very high peak
values were detected in some individuals of both
groups. The same holds true for three other markers
assessed in the same study (IL-1β, IL-8, and IL-10),
suggesting that the African cohorts may be exposed to
additional immunological challenges even in the absence
of malaria. On the other hand, our threshold values for
IL-12 and TNF-α corresponded well to their mean
values of healthy controls.
In our study, no correlation was found between the
inflammatory mediator levels and the clinical parameters
either before or after periodontal treatment. This is in
agreement with other studies showing poor and incon-
sistent correlations between changes in the levels of
inflammatory markers and changes in the clinical peri-
odontal status after therapy, reduction of periodontal
pathogens, and reduction of serum IgG antibody levels
to periodontal microbiota [7, 17, 25]. It seems that
serum levels of specific cytokines or acute-phase pro-
teins do not reflect the clinical periodontal health status
independently; preexisting susceptibility for systemic in-
flammation may influence the individual response. How-
ever, the reduction of most of the peak values, defined
as greater than the mean+2 SD in periodontally healthy
subjects, can be attributed to periodontal therapy. A
marked increase of CRP has been reported 24 h after
instrumentation [21], indicating that patients undergoing
periodontal treatment experience short-term perturbations
of systemic inflammation. Due to the timing of our trial,
we could not corroborate the existence of short-term
peaks of some of the acute-phase proteins, but even if
they exist, it seems that they are short-lived, as they
were undetectable at M3 in our study.
Systemic amoxicillin plus metronidazole significantly im-
proved clinical outcomes of periodontal therapy, similar to
previous studies [26]. No significant difference on the biologic
response to therapy was, however, found between the two
groups.We assume that the mechanical removal of pathogenic
bacteria by SRP was sufficient to suppress peak values of
inflammatory biomarkers.
Conclusion
Subjects with untreated periodontitis may show isolated high
peaks for one or several inflammatory markers in serum.
Nonsurgical periodontal treatment with or without antibiotics
reduced most of these peak levels.
Table 4 Levels of 13 serum biomarkers with a detection frequency of >75 % in periodontitis patients per treatment group, at baseline and M3. Data are
means (standard deviation), n=40 participants
Parameters Baseline Month 3 p
Placebo Test Placebo Test BL-M3
Participants, n 21 19 21 19
IL-1ra, pg/ml 12.6 (29.3) 5.8 (8.5) 0.5 (1.2) 2.0 (7.3) <0.001
IL-8, pg/ml 5.7 (8.6) 6.7 (6.3) 5.6 (9.5) 6.1 (7.3) n.s.
IL-12-p70, pg/ml 25.8 (20.9) 30.0 (30.6) 5.8 (4.6) 8.4 (6.1) <0.001
MIP-1β, pg/ml 189.4 (157.9) 157.0 (74.4) 97.0 (50.1) 99.0 (52.6) <0.001
VEGF, pg/ml 237.6 (244.3) 354.3 (544.8) 148.7 (130.0) 499.0 (1,253.4) 0.002
α2M, mg/ml 1.3 (0.6) 1.6 (0.5) 1.7 (0.3) 1.6 (0.3) 0.04
CRP, μg/ml 5.7 (8.1) 6.4 (11.7) 4.6 (4.4) 5.1 (7.6) n.s.
Haptoglobin, mg/ml 1.0 (1.5) 2.3 (2.5) 2.8 (2.7) 3.2 (3.0) 0.004
Serum amyloid P, μg/ml 56.2 (20.0) 56.5 (13.9) 67.1 (25.7) 58.2 (13.5) 0.02
Ferritin, ng/ml 117.0 (166.9) 109.4 (122.6) 99.0 (128.4) 97.0 (107.0) 0.002
Fibrinogen, μg/ml 2.6 (0.9) 2.3 (1.0) 1.9 (0.6) 1.8 (0.6) 0.001
Procalcitonin, ng/ml 2.5 (2.1) 2.3 (1.8) 0.5 (0.6) 0.5 (0.8) <0.001
Serum amyloid A, μg/ml 8.9 (7.0) 6.5 (5.2) 3.6 (3.5) 3.7 (6.7) <0.001
IL-1ra interleukin-1 receptor antagonist, IL-8, interleukin-8, IL-12 interleukin-12, MIP-1β macrophage inflammatory protein beta, VEGF vascular
endothelial growth factor, α2M alpha-2 macroglobulin, CRPC-reactive protein, n.s. not significant
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